SynthesisBMC infectious diseases2022
Performance of BioFire Blood Culture Identification 2 Panel (BCID2) for the detection of bloodstream pathogens and their associated resistance markers: a systematic review and meta-analysis of diagnostic test accuracy studies.
Synthesis in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Rapid Diagnostic Tests and Antimicrobial Stewardship Programs for the Management of Bloodstream Infection: What Is Their Relative Contribution to Improving Clinical Outcomes? A Systematic Review and Network Meta-analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Pooled it
- Comparison of Five Assays for Rapid Antimicrobial Susceptibility Testing (RAST), Including Disk Diffusion, MIC-Based Systems, and Genotypic Methods: A Prospective Evaluation.Infectious diseases and therapy · 2026Article
- A rapid, inexpensive diagnostic for bacterial pathogen and resistance detection in resource-limited settings.Science advances · 2026Article
- Diagnostic performance and cost-effectiveness of a combined rapid antimicrobial susceptibility testing (RAST) and lateral flow immunochromatographic assay-based workflow for bloodstream infections.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Rapid microbiological diagnostics for sepsis in critical care: integrating technological advances with antimicrobial stewardship.Acute and critical care · 2026Article
- Multiplex-PCR Identification of Positive Blood Cultures: Pathogen Epidemiology, Resistance Determinants, and the Economic and Interpretive Cost of Qualitative Rapid Diagnosis.Diagnostics (Basel, Switzerland) · 2026Article
- Evaluation of Q-linea ASTar rapid phenotypic antimicrobial susceptibility testing and potential impact in patients with gram-negative bloodstream infections.Microbiology spectrum · 2026Article
- Point-Counterpoint: The "obsoletogram"-are annual hospital antibiograms still relevant?Journal of clinical microbiology · 2026Article
- Invasive Candidiasis in Critically Ill Patients: Fundamental Concepts and Future Directions.Chest · 2026Review
- [Advances in integrated antimicrobial resistance diagnostics: quantitative, qualitative and AI-driven approaches].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2026Review
- Impact of a Rapid Change in Beta-lactam Resistance Epidemiology on the Management of Patients With Bloodstream Infections.Open forum infectious diseases · 2026Article
- Programmable CRISPR-Cas diagnostic platforms for rapid detection of uropathogens and antimicrobial resistance.Archives of microbiology · 2026Review
- Genomic Insights into Carbapenem-ResistantJournal of clinical medicine · 2026Article
- Evaluation of the Performance of Novel Gram-Negative and Gram-Positive Sepsis Panels for the Rapid Diagnosis of Bloodstream Infections.Diagnostics (Basel, Switzerland) · 2026Article
- Rapid commercial CTX-M diagnostics: Performance, limitations and clinical impact.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- BacT-Seq, a Nanopore-Based Whole-Genome Sequencing Workflow Prototype for Rapid and Accurate Pathogen Identification and Resistance Prediction from Positive Blood Cultures: A Feasibility Study.Diagnostics (Basel, Switzerland) · 2026Article
- Diagnostic Accuracy of the Biofire FilmArray Blood Culture Identification 2 (BCID2) for Bloodstream Infections in Limpopo, South Africa.Infection and drug resistance · 2026Article
- Article
- Impact of Rapid Molecular Diagnostic Testing on Outcomes of Patients With Vancomycin-Resistant Enterococcal Bacteremia.Open forum infectious diseases · 2026Article
- A Review on the Current and Future State of Urinary Tract Infection Diagnostics.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly identification of bloodstream pathogens and their associated antimicrobial resistance may shorten time to optimal therapy in patients with sepsis. The BioFire Blood Culture Identification 2 Panel (BCID2) is a novel multiplex PCR detecting 43 targets directly from positive blood cultures, reducing turnaround times.
methodsWe have performed a systematic review and meta-analysis of diagnostic test accuracy studies to assess the BCID2 performance for pathogen identification and resistance markers detection compared to gold standard culture-based methods (including phenotypic and/or genotypic characterization).
resultsNine studies were identified reporting data to build 2 × 2 tables for each BCID2 target, including 2005 blood cultures. The pooled specificity of the assay was excellent (> 97%) across most subgroups of targets investigated, with a slightly broader confidence interval for S. epidermidis (98.1%, 95% CI 93.1 to 99.5). Pooled sensitivity was also high for the major determinants of bloodstream infection, including Enterobacterales (98.2%, 95% CI 96.3 to 99.1), S. aureus (96.0%, 95% CI 90.4 to 98.4), Streptococcus spp. (96.7%, 95% CI 92.8 to 98.5), P. aeruginosa (92.7%, 95% CI 83.1 to 97.0), E. faecalis (92.3%, 95% CI 83.5 to 96.6), as well as bla
conclusionsBCID2 showed good performance for detecting major determinants of bloodstream infection and could support early antimicrobial treatment, especially for ESBL or carbapenemase-producing Gram-negative bacilli and methicillin-resistant S. aureus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.